<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02992574</url>
  </required_header>
  <id_info>
    <org_study_id>1602</org_study_id>
    <secondary_id>CTRI/2016/12/007532</secondary_id>
    <nct_id>NCT02992574</nct_id>
  </id_info>
  <brief_title>Trial Evaluating Role of Post Mastectomy Radiotherapy in Women With Node Negative Early Breast Cancer</brief_title>
  <acronym>PMRT-NNBC</acronym>
  <official_title>Post-Mastectomy Radiation Therapy in High Risk, Node Negative Women With Early Breast Cancer (PMRT-NNBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tata Memorial Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tata Memorial Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postmastectomy radiotherapy (PMRT) is unequivocally beneficial in reducing the recurrences as
      well as improving survival in node positive breast cancer patients. PMRT for women with T1-T2
      tumors and negative axillary nodes is not generally warranted because of the presumed low
      risk of recurrence in this population as a whole. However, in the setting of multiple adverse
      prognostic factors, the recurrence risk approaches and in some cases surpasses the risk of
      recurrence documented for patients with one to three positive lymph nodes. Numerous
      retrospective series have reported the outcome and patterns of failure for post-mastectomy
      patients treated without radiation. Many of these series have analyzed several high risk
      factors which were predictive of loco-regional recurrence wherein the role of adjuvant
      post-mastectomy radiation can be considered. Some authors have used combinations of
      prognostic factors, such as age, tumour size, grade, receptor status, Her2neu status and
      lympho-vascular space invasion to define subgroups with more specific risks of loco-regional
      recurrence than single factors alone. The current trial hypothesizes that &quot;Post-mastectomy
      radiation in high risk, node negative early breast cancer patients decreases rates of
      loco-regional recurrence and improves disease free survival&quot; and propose to address the
      question in randomized setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2016</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2028</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm Experimental Post Mastectomy Radiotherapy Arm No Intervention: No Post Mastectomy Radiotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chest wall recurrence</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional recurrence</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis-free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Morbidity of radiotherapy</measure>
    <time_frame>4 weeks from the start of radiotherapy</time_frame>
    <description>RTOG Acute radiation morbidity scoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Morbidity of radiotherapy</measure>
    <time_frame>6 months from end of radiotherapy to 5 years</time_frame>
    <description>RTOG Late radiation morbidity scoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>5 years post surgery</time_frame>
    <description>Quality of life will be assesses by EORTC QLQ C-30 core questionnaire and the breast cancer specific module BR-23 questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1022</enrollment>
  <condition>Breastcancer</condition>
  <arm_group>
    <arm_group_label>Post Mastectomy Radiation Therapy (PMRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Post mastectomy radiotherapy will be given</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation (No PMRT)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No adjuvant radiotherapy will be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Post Mastectomy Radiation therapy</intervention_name>
    <description>Post mastectomy radiotherapy to the chest wall and ipsilateral supra-clavicular fossa to a dose of 40 Gy in 15 fractions over 3 weeks</description>
    <arm_group_label>Post Mastectomy Radiation Therapy (PMRT)</arm_group_label>
    <other_name>PMRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with unilateral pT1,2N0M0 breast cancer or multifocal breast cancer if largest
             discrete tumour at least 2cm or if the tumour area comprises multiple small adjacent
             foci of invasive carcinoma then overall maximum dimension taken. This must be greater
             than 2cm.

          -  Upfront total mastectomy (with minimum 1 mm margin clear of invasive cancer or DCIS)
             and axillary staging procedure (clearance, sampling or SNB)

          -  T2 tumors with one risk factor or T1 tumors with any of the following two high risk
             factors such as presence of high grade, lymphovascular invasion, ER/PR negative, HER2
             positivity, age &lt; 35 years.

          -  Fit to receive adjuvant radiation +/- chemotherapy (if indicated) +/- hormonal therapy
             (if indicated)

          -  Written, informed consent

        Exclusion Criteria:

          -  Any pTis/3/4, M1 patients

          -  Patients who have any pathologically involved axillary nodes (micro-metastasis may be
             allowed)

          -  Patients who have undergone neoadjuvant systemic therapy.

          -  Previous or concurrent malignancy other than non melanomatous skin cancer and
             carcinoma in situ of the cervix

          -  Pregnancy

          -  Bilateral breast cancer

          -  Not fit for surgery, radiotherapy or adjuvant systemic therapy

          -  Unable or unwilling to give informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tabassum Wadasadawala, MBBS,MD,DNB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor, Radiation Oncology, Tata Memorial Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tabassum Wadasadawala, MBBS,MD,DNB</last_name>
    <phone>02227405078</phone>
    <email>twadasadawala@actrec.gov.in</email>
  </overall_contact>
  <location>
    <facility>
      <name>Max Super Speciality Hospital(A unit of Devki Devi Foundation)</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110017</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anil K Anand, MBBS,MD</last_name>
      <phone>9810398838</phone>
      <email>akanand@maxhealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Anil K Anand, MBBS,MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kolhapur Cancer Centre Pvt Ltd</name>
      <address>
        <city>Kolhapur</city>
        <state>Maharashtra</state>
        <zip>416234</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yogesh Anap, MBBS,MD,DNB</last_name>
      <phone>9420635556</phone>
      <email>yogesh.anap1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yogesh Anap, MBBS,MD,DNB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Centre</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tabassum Wadasadawala, MBBS,MD,DNB</last_name>
      <phone>02227405078</phone>
      <email>twadasadawala@actrec.gov.in</email>
    </contact>
    <investigator>
      <last_name>Tabassum Wadasadawala, MBBS,MD,DNB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Post Graduate Institute of Medical Education &amp; Research</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Budhi S Yadav, MBBS,MD</last_name>
      <phone>9815981176</phone>
      <email>drbudhi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Budhi S Yadav, MBBS,MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Max Super Speciality Hospital, Shalimar Bagh</name>
      <address>
        <city>Delhi</city>
        <zip>110088</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vineeta Goel, MBBS, DNB</last_name>
      <phone>9818045469</phone>
      <email>vineetagoel@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Vineeta Goel, MBBS,DNB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2016</study_first_submitted>
  <study_first_submitted_qc>December 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2016</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tata Memorial Centre</investigator_affiliation>
    <investigator_full_name>Dr. Tabassum Wadasadawala</investigator_full_name>
    <investigator_title>Associate Professor, Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>Post-Mastectomy Radiation</keyword>
  <keyword>Node Negative</keyword>
  <keyword>Early breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

